| VETO Stock | | | EUR 78.20 0.20 0.26% |
CEO
Mr. Matthieu Frechin has served as Chief Executive Officer of Vetoquinol SA as of April 1, 2010. He joined Vetoquinol on April 2, 2001 where he served in the office of the Chief Executive. While there, he was in charge of marketing the canine products range in the France sales division at Paris. On December 1, 2001, he was appointed Director of Sales Pet Range. In September 2004, Mr. Frechin was appointed Group Director Strategy and Development and held this post until August 21, 2006. He was appointed Deputy Chief Executive of the Company by decision of the Board of Directors dated August 21, 2006. He was a Member of the Executive Committee of the Company since its inception in September 2004. He is also a Member of the Strategy Committee. He was a Director of the Company since May 22, 2006. He began his career in the human health sector at Pfizer, later moving to Sanofi, and then to Servier Laboratories. He is also Member of the Supervisory Board of Soparfin SCA. He holds a Doctorate in Pharmacy, graduated from the Faculty of Pharmacy of Universite Henri Poincare Nancy I in 1995, and holds a diploma in Industrial Systems Engineering, specialized in Marketing. since 2010.
| Age | 54 |
| Tenure | 14 years |
| Phone | 33 3 84 62 55 55 |
| Web | https://www.vetoquinol.com |
Vetoquinol Management Efficiency
The company has return on total asset
(ROA) of
0.0774 % which means that it generated a profit of $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.11 %, meaning that it generated $0.11 on every $100 dollars invested by stockholders. Vetoquinol's management efficiency ratios could be used to measure how well Vetoquinol manages its routine affairs as well as how well it operates its assets and liabilities.
Vetoquinol has accumulated 7.07
M in total debt with debt to equity ratio
(D/E) of 1.8, which is about average as compared to similar companies. Vetoquinol has a current ratio of 3.19, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vetoquinol until it has trouble settling it off, either with new capital or with free cash flow. So, Vetoquinol's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vetoquinol sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vetoquinol to invest in growth at high rates of return. When we think about Vetoquinol's use of debt, we should always consider it together with cash and equity.
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. Vetoquinol SA was founded in 1933 and is headquartered in Lure, France. Vetoquinol operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 2004 people. Vetoquinol (VETO) is traded on Euronext Paris in France and employs 2,621 people.
Management Performance
Vetoquinol Leadership Team
Elected by the shareholders, the Vetoquinol's board of directors comprises two types of representatives: Vetoquinol inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vetoquinol. The board's role is to monitor Vetoquinol's management team and ensure that shareholders' interests are well served. Vetoquinol's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vetoquinol's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthieu Frechin, CEO, Director and Member of Strategy Committee | |
| Hans Hollegien, Member of the Executive Committee, Group Director - Marketing and Communication | |
| Philippe Gruet, Chief Officer | |
| Isabelle ProustCabrera, Member of the Executive Committee, Group Director - Human Resources | |
| Xavier Berthet, Director Communications | |
| Laurent Thore, Legal Partnerships | |
| Dominique Derveaux, Member of the Executive Committee, Group Director - Europe | |
| Regis Monteil, Group Director of Fin. and Legal | |
| Sandrine Perrier, Chief Officer | |
| Alain Masson, COO and Chief Pharmacist | |
Vetoquinol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vetoquinol a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Vetoquinol Stock
Vetoquinol financial ratios help investors to determine whether Vetoquinol Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vetoquinol with respect to the benefits of owning Vetoquinol security.